GLUE
HealthcareMonte Rosa Therapeutics, Inc.
$16.03-0.01 (-0.06%)
Prev Close
$16.04
Open
$15.98
High
$16.62
Low
$15.95
Volume
596.5K
Market Cap
$1.15B
P/E
—
Div Yield
—
Over the past 12 months, insider activity at Monte Rosa Therapeutics, Inc. (GLUE) has been dominated by selling, with 1 insider purchase totaling $58.4K and 13 insider sales totaling $1.61M. The most recent insider transaction was by Dunn Edmund (officer: Principal Accounting Officer), who sold $2.5K worth of shares on Mar 5, 2026. Monte Rosa Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $1.15B.
Buys (12M)
1
$58.4K
Sells (12M)
13
$1.61M
Net Activity
Net Seller
$1.56M
Active Insiders
7
last 12 mo
GLUE Price Chart
GLUE Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 5, 2026↗ | Dunn Edmund | officer: Principal Accounting Officer | Sell | 139 | $17.96 | $2.5K | 22,554 |
| Mar 4, 2026↗ | Warmuth Markus | director, officer: President & CEO | Sell | 10,932 | $17.92 | $195.9K | 613,471 |
| Mar 2, 2026↗ | Dunn Edmund | officer: Principal Accounting Officer | Sell | 25,700 | $18.09 | $464.9K | 22,693 |
| Feb 24, 2026↗ | Janku Filip | officer: Chief Medical Officer | Sell | 18,378 | $19.50 | $358.3K | 65,837 |
| Jan 9, 2026↗ | Warmuth Markus | director, officer: President & CEO | Sell | 5,466 | $23.49 | $128.4K | 620,696 |
| Jan 5, 2026↗ | Champoux Jennifer | officer: Chief Operating Officer | Sell | 2,629 | $15.17 | $39.9K | 62,371 |
| Jan 5, 2026↗ | Dunn Edmund | Principal Accounting Officer | Sell | 2,078 | $15.17 | $31.5K | 22,693 |
| Jan 5, 2026↗ | Janku Filip | officer: Chief Medical Officer | Sell | 3,155 | $15.17 | $47.9K | 75,026 |
| Jan 5, 2026↗ | Nickson Philip | officer: Chief Business & Legal Officer | Sell | 3,155 | $15.17 | $47.9K | 60,845 |
| Jan 5, 2026↗ | Townson Sharon | officer: Chief Scientific Officer | Sell | 3,155 | $15.17 | $47.9K | 67,845 |
| Jan 5, 2026↗ | Warmuth Markus | director, officer: President & CEO | Sell | 10,135 | $15.17 | $153.7K | 624,403 |
| Jan 2, 2026↗ | Janku Filip | Chief Medical Officer | Sell | 3,155 | $15.17 | $47.9K | 0 |
| Jan 2, 2026↗ | Nickson Philip | Chief Business & Legal Officer | Sell | 3,155 | $15.17 | $47.9K | 0 |
| Mar 24, 2025↗ | Leo Chandra P. | Director | Buy | 10,000 | $5.84 | $58.4K | 0 |
| Oct 30, 2024↗ | Versant Venture Capital VI, L.P. | Sell | 157,895 | $9.44 | $1.49M | 2,007,950 | |
| Sep 24, 2024↗ | Versant Venture Capital VI, L.P. | Sell | 1,132,566 | $6.53 | $7.40M | 5,099,340 | |
| Sep 13, 2024↗ | Versant Venture Capital VI, L.P. | Sell | 567,213 | $6.00 | $3.40M | 6,257,220 | |
| Jul 9, 2024↗ | Dunn Edmund | Principal Accounting Officer | Sell | 1,610 | $3.83 | $6.2K | 13,944 |
| Jun 5, 2024↗ | Dunn Edmund | Principal Accounting Officer | Sell | 1,207 | $4.04 | $4.9K | 15,554 |
| Jun 30, 2021↗ | BASKETT FOREST | 10% Owner | Buy | 1,050,000 | $19.00 | $19.95M | 7,692,300 |
| Jun 30, 2021↗ | Behbahani Ali | Director | Buy | 1,050,000 | $19.00 | $19.95M | 7,692,300 |
| Jun 30, 2021↗ | Bolzon Bradley J PhD | Director | Buy | 157,895 | $19.00 | $3.00M | 2,097,940 |
| Jun 30, 2021↗ | Chang Carmen | 10% Owner | Buy | 1,050,000 | $19.00 | $19.95M | 7,692,300 |
| Jun 30, 2021↗ | Cormorant Asset Management, LP | Buy | 600,000 | $19.00 | $11.40M | 3,202,200 | |
| Jun 30, 2021↗ | Florence Anthony A. Jr. | 10% Owner | Buy | 1,050,000 | $19.00 | $19.95M | 7,692,300 |
| Jun 30, 2021↗ | Landsman Liza | 10% Owner | Buy | 1,050,000 | $19.00 | $19.95M | 7,692,300 |
| Jun 30, 2021↗ | Makhzoumi Mohamad | 10% Owner | Buy | 1,050,000 | $19.00 | $19.95M | 7,692,300 |
| Jun 30, 2021↗ | MAKOWER JOSHUA | 10% Owner | Buy | 1,050,000 | $19.00 | $19.95M | 7,692,300 |
| Jun 30, 2021↗ | Mathers Edward T | 10% Owner | Buy | 1,050,000 | $19.00 | $19.95M | 7,692,300 |
| Jun 30, 2021↗ | New Enterprise Associates 17, L.P. | 10% Owner | Buy | 1,050,000 | $19.00 | $19.95M | 7,692,300 |
| Jun 30, 2021↗ | SANDELL SCOTT D | 10% Owner | Buy | 1,050,000 | $19.00 | $19.95M | 7,692,300 |
| Jun 30, 2021↗ | Sonsini Peter W. | 10% Owner | Buy | 1,050,000 | $19.00 | $19.95M | 7,692,300 |
| Jun 30, 2021↗ | Versant Venture Capital VI, L.P. | 10% Owner | Buy | 157,895 | $19.00 | $3.00M | 2,097,940 |
| Jun 30, 2021↗ | Walker Paul Edward | 10% Owner | Buy | 1,050,000 | $19.00 | $19.95M | 7,692,300 |
| Jun 30, 2021↗ | Yang Rick | 10% Owner | Buy | 1,050,000 | $19.00 | $19.95M | 7,692,300 |
GLUE Insider Buying Activity
The following table shows recent insider purchases of Monte Rosa Therapeutics, Inc. (GLUE) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 24, 2025↗ | Leo Chandra P. | Director | Buy | 10,000 | $5.84 | $58.4K | 0 |
| Jun 30, 2021↗ | BASKETT FOREST | 10% Owner | Buy | 1,050,000 | $19.00 | $19.95M | 7,692,300 |
| Jun 30, 2021↗ | Behbahani Ali | Director | Buy | 1,050,000 | $19.00 | $19.95M | 7,692,300 |
| Jun 30, 2021↗ | Bolzon Bradley J PhD | Director | Buy | 157,895 | $19.00 | $3.00M | 2,097,940 |
| Jun 30, 2021↗ | Chang Carmen | 10% Owner | Buy | 1,050,000 | $19.00 | $19.95M | 7,692,300 |
| Jun 30, 2021↗ | Cormorant Asset Management, LP | Buy | 600,000 | $19.00 | $11.40M | 3,202,200 | |
| Jun 30, 2021↗ | Florence Anthony A. Jr. | 10% Owner | Buy | 1,050,000 | $19.00 | $19.95M | 7,692,300 |
| Jun 30, 2021↗ | Landsman Liza | 10% Owner | Buy | 1,050,000 | $19.00 | $19.95M | 7,692,300 |
| Jun 30, 2021↗ | Makhzoumi Mohamad | 10% Owner | Buy | 1,050,000 | $19.00 | $19.95M | 7,692,300 |
| Jun 30, 2021↗ | MAKOWER JOSHUA | 10% Owner | Buy | 1,050,000 | $19.00 | $19.95M | 7,692,300 |
| Jun 30, 2021↗ | Mathers Edward T | 10% Owner | Buy | 1,050,000 | $19.00 | $19.95M | 7,692,300 |
| Jun 30, 2021↗ | New Enterprise Associates 17, L.P. | 10% Owner | Buy | 1,050,000 | $19.00 | $19.95M | 7,692,300 |
| Jun 30, 2021↗ | SANDELL SCOTT D | 10% Owner | Buy | 1,050,000 | $19.00 | $19.95M | 7,692,300 |
| Jun 30, 2021↗ | Sonsini Peter W. | 10% Owner | Buy | 1,050,000 | $19.00 | $19.95M | 7,692,300 |
| Jun 30, 2021↗ | Versant Venture Capital VI, L.P. | 10% Owner | Buy | 157,895 | $19.00 | $3.00M | 2,097,940 |
| Jun 30, 2021↗ | Walker Paul Edward | 10% Owner | Buy | 1,050,000 | $19.00 | $19.95M | 7,692,300 |
| Jun 30, 2021↗ | Yang Rick | 10% Owner | Buy | 1,050,000 | $19.00 | $19.95M | 7,692,300 |
GLUE Insider Selling Activity
The following table shows recent insider sales of Monte Rosa Therapeutics, Inc. (GLUE) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 5, 2026↗ | Dunn Edmund | officer: Principal Accounting Officer | Sell | 139 | $17.96 | $2.5K | 22,554 |
| Mar 4, 2026↗ | Warmuth Markus | director, officer: President & CEO | Sell | 10,932 | $17.92 | $195.9K | 613,471 |
| Mar 2, 2026↗ | Dunn Edmund | officer: Principal Accounting Officer | Sell | 25,700 | $18.09 | $464.9K | 22,693 |
| Feb 24, 2026↗ | Janku Filip | officer: Chief Medical Officer | Sell | 18,378 | $19.50 | $358.3K | 65,837 |
| Jan 9, 2026↗ | Warmuth Markus | director, officer: President & CEO | Sell | 5,466 | $23.49 | $128.4K | 620,696 |
| Jan 5, 2026↗ | Champoux Jennifer | officer: Chief Operating Officer | Sell | 2,629 | $15.17 | $39.9K | 62,371 |
| Jan 5, 2026↗ | Dunn Edmund | Principal Accounting Officer | Sell | 2,078 | $15.17 | $31.5K | 22,693 |
| Jan 5, 2026↗ | Janku Filip | officer: Chief Medical Officer | Sell | 3,155 | $15.17 | $47.9K | 75,026 |
| Jan 5, 2026↗ | Nickson Philip | officer: Chief Business & Legal Officer | Sell | 3,155 | $15.17 | $47.9K | 60,845 |
| Jan 5, 2026↗ | Townson Sharon | officer: Chief Scientific Officer | Sell | 3,155 | $15.17 | $47.9K | 67,845 |
| Jan 5, 2026↗ | Warmuth Markus | director, officer: President & CEO | Sell | 10,135 | $15.17 | $153.7K | 624,403 |
| Jan 2, 2026↗ | Janku Filip | Chief Medical Officer | Sell | 3,155 | $15.17 | $47.9K | 0 |
| Jan 2, 2026↗ | Nickson Philip | Chief Business & Legal Officer | Sell | 3,155 | $15.17 | $47.9K | 0 |
| Oct 30, 2024↗ | Versant Venture Capital VI, L.P. | Sell | 157,895 | $9.44 | $1.49M | 2,007,950 | |
| Sep 24, 2024↗ | Versant Venture Capital VI, L.P. | Sell | 1,132,566 | $6.53 | $7.40M | 5,099,340 | |
| Sep 13, 2024↗ | Versant Venture Capital VI, L.P. | Sell | 567,213 | $6.00 | $3.40M | 6,257,220 | |
| Jul 9, 2024↗ | Dunn Edmund | Principal Accounting Officer | Sell | 1,610 | $3.83 | $6.2K | 13,944 |
| Jun 5, 2024↗ | Dunn Edmund | Principal Accounting Officer | Sell | 1,207 | $4.04 | $4.9K | 15,554 |
GLUE Insiders
Similar Stocks to GLUE
VRTX
Vertex Pharmaceuticals Incorporated
$470.20-1.66%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$743.51-0.41%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$313.45-1.19%
$42.07B
INSM
Insmed Incorporated
$139.06-0.33%
$30.07B
UTHR
United Therapeutics Corporation
$536.12+0.97%
$23.50B
MRNA
Moderna, Inc.
$52.56-1.89%
$20.76B
ROIV
Roivant Sciences Ltd.
$28.06-1.44%
$20.08B
RPRX
Royalty Pharma plc
$45.65-0.57%
$19.56B